<div class="table-responsive">
    <table class="table table-striped table-hover">
        <thead>
            <tr>
                
                <th scope="col">
                    <a href="?cresstrial=13980&amp;modal=1&amp;valnames=arms&amp;order=created_at">Created at</a>
                </th>
                <th scope="col">Source</th>
                
                <th scope="col">Raw Value</th>
                <th scope="col">Validated value</th>
            </tr>
        </thead>
        <tbody>
            
            <tr class="histvalue-row" histvalueid="316281" class="table-">
                
                <td>June 24, 2021, 2:30 a.m.</td>
                <td>irct</td>
                
                <td class="histvalue-container">
                    

        <p class="arms">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;TODO PlaceboControl group in the second cohort: In 2 cities (Zanjan and Yazd) 20% of people (1200 people) receive a placebo after random allocation. The intervention involves an intramuscular injection of a dose of aluminum hydroxide on days 0, 28 and 56. This placebo is made by the Finlay Institute of Vaccines.&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;Placebo&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;TODO PreventionIntervention group in the second cohort: In two cities (Zanjan and Yazd) 80% of people (4800 people) receive the intervention (vaccine) after random allocation. The intervention includes: a 2-dose program + a booster dose (days 0, 28, 56). The booster dose of the candidate vaccine is Sobrana Plus (50 micrograms d-RBD +, IM 0.5 ml). This vaccine is made by the Finlay Institute of Vaccines.&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;TODO PlaceboControl group in the first cohort: In 6 cities (Isfahan, Babol, Bandar Abbas, Sari, Kerman and Hamedan) 20% of people (3600 people) receive a placebo after random allocation. The intervention involves an intramuscular injection of a dose of aluminum hydroxide on days 0 and 28. This placebo is made by the Finlay Institute of Vaccines.&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;Placebo&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;TODO PreventionIntervention group in the first cohort: In 6 cities (Isfahan, Babol, Bandar Abbas, Sari, Kerman and Hamedan) 80% of people (14,400 people) receive the intervention (vaccine) after random allocation. Intervention is included intramuscular injection of vaccine candidates with conjugation of 25 \u03bcg RBD to tetanus toxin in a 2-dose program (days 0 and 28). This vaccine is made by the Finlay Institute of Vaccines.&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}]
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="arms validated">
            [{&quot;arm_notes&quot;: &quot;25 \u03bcg;2;Days0-28&quot;, &quot;treatment_id&quot;: 515, &quot;treatment_name&quot;: &quot;Finlay-fr-2 anti-sars-cov-2 vaccine&quot;, &quot;treatment_type&quot;: &quot;Protein subunit&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;three doses;Days 0-28-56;booster at day 56 is finlay-fr-1a (50 \u03bcg)&quot;, &quot;treatment_id&quot;: 1519, &quot;treatment_name&quot;: &quot;Finlay-fr-1a anti-sars-cov-2 vaccine+finlay-fr-2 anti-sars-cov-2 vaccine&quot;, &quot;treatment_type&quot;: &quot;Protein subunit&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: 2187, &quot;treatment_name&quot;: &quot;Placebo&quot;, &quot;treatment_type&quot;: &quot;Placebo&quot;, &quot;pharmacological_treatment&quot;: &quot;Placebo&quot;}]
        </p>
        
    
                </td>
            </tr>
            
            <tr class="histvalue-row" histvalueid="314296" class="table-">
                
                <td>April 25, 2021, 1 a.m.</td>
                <td>irct</td>
                
                <td class="histvalue-container">
                    

        <p class="arms">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;TODO PlaceboControl group in the second cohort: In 2 cities (Zanjan and Yazd) 20% of people (1200 people) receive a placebo after random allocation. The intervention involves an intramuscular injection of a dose of aluminum hydroxide on days 0, 28 and 56. This placebo is made by the Finlay Institute of Vaccines.&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;Placebo&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;TODO PreventionIntervention group in the second cohort: In two cities (Zanjan and Yazd) 80% of people (4800 people) receive the intervention (vaccine) after random allocation. The intervention includes: a 2-dose program + a booster dose (days 0, 28, 56). The booster dose of the candidate vaccine is Subrana 01 (50 micrograms d-RBD +, IM 0.5 ml). This vaccine is made by the Finlay Institute of Vaccines.&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;TODO PlaceboControl group in the first cohort: In 6 cities (Isfahan, Babol, Bandar Abbas, Sari, Kerman and Hamedan) 20% of people (3600 people) receive a placebo after random allocation. The intervention involves an intramuscular injection of a dose of aluminum hydroxide on days 0 and 28. This placebo is made by the Finlay Institute of Vaccines.&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;Placebo&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;TODO PreventionIntervention group in the first cohort: In 6 cities (Isfahan, Babol, Bandar Abbas, Sari, Kerman and Hamedan) 80% of people (14,400 people) receive the intervention (vaccine) after random allocation. Intervention is included intramuscular injection of vaccine candidates with conjugation of 25 \u03bcg RBD to tetanus toxin in a 2-dose program (days 0 and 28). This vaccine is made by the Finlay Institute of Vaccines.&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}]
        </p>
    

                </td>
                <td class="histvalue-container">
                    

                </td>
            </tr>
            
        </tbody>
    </table>
</div>
Created at	Source	Raw Value	Validated value
June 24, 2021, 2:30 a.m.	irct	[{"arm_notes": "", "treatment_id": null, "treatment_name": "TODO PlaceboControl group in the second cohort: In 2 cities (Zanjan and Yazd) 20% of people (1200 people) receive a placebo after random allocation. The intervention involves an intramuscular injection of a dose of aluminum hydroxide on days 0, 28 and 56. This placebo is made by the Finlay Institute of Vaccines.", "treatment_type": "TODO", "pharmacological_treatment": "Placebo"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "TODO PreventionIntervention group in the second cohort: In two cities (Zanjan and Yazd) 80% of people (4800 people) receive the intervention (vaccine) after random allocation. The intervention includes: a 2-dose program + a booster dose (days 0, 28, 56). The booster dose of the candidate vaccine is Sobrana Plus (50 micrograms d-RBD +, IM 0.5 ml). This vaccine is made by the Finlay Institute of Vaccines.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "TODO PlaceboControl group in the first cohort: In 6 cities (Isfahan, Babol, Bandar Abbas, Sari, Kerman and Hamedan) 20% of people (3600 people) receive a placebo after random allocation. The intervention involves an intramuscular injection of a dose of aluminum hydroxide on days 0 and 28. This placebo is made by the Finlay Institute of Vaccines.", "treatment_type": "TODO", "pharmacological_treatment": "Placebo"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "TODO PreventionIntervention group in the first cohort: In 6 cities (Isfahan, Babol, Bandar Abbas, Sari, Kerman and Hamedan) 80% of people (14,400 people) receive the intervention (vaccine) after random allocation. Intervention is included intramuscular injection of vaccine candidates with conjugation of 25 \u03bcg RBD to tetanus toxin in a 2-dose program (days 0 and 28). This vaccine is made by the Finlay Institute of Vaccines.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]	[{"arm_notes": "25 \u03bcg;2;Days0-28", "treatment_id": 515, "treatment_name": "Finlay-fr-2 anti-sars-cov-2 vaccine", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "three doses;Days 0-28-56;booster at day 56 is finlay-fr-1a (50 \u03bcg)", "treatment_id": 1519, "treatment_name": "Finlay-fr-1a anti-sars-cov-2 vaccine+finlay-fr-2 anti-sars-cov-2 vaccine", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]
April 25, 2021, 1 a.m.	irct	[{"arm_notes": "", "treatment_id": null, "treatment_name": "TODO PlaceboControl group in the second cohort: In 2 cities (Zanjan and Yazd) 20% of people (1200 people) receive a placebo after random allocation. The intervention involves an intramuscular injection of a dose of aluminum hydroxide on days 0, 28 and 56. This placebo is made by the Finlay Institute of Vaccines.", "treatment_type": "TODO", "pharmacological_treatment": "Placebo"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "TODO PreventionIntervention group in the second cohort: In two cities (Zanjan and Yazd) 80% of people (4800 people) receive the intervention (vaccine) after random allocation. The intervention includes: a 2-dose program + a booster dose (days 0, 28, 56). The booster dose of the candidate vaccine is Subrana 01 (50 micrograms d-RBD +, IM 0.5 ml). This vaccine is made by the Finlay Institute of Vaccines.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "TODO PlaceboControl group in the first cohort: In 6 cities (Isfahan, Babol, Bandar Abbas, Sari, Kerman and Hamedan) 20% of people (3600 people) receive a placebo after random allocation. The intervention involves an intramuscular injection of a dose of aluminum hydroxide on days 0 and 28. This placebo is made by the Finlay Institute of Vaccines.", "treatment_type": "TODO", "pharmacological_treatment": "Placebo"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "TODO PreventionIntervention group in the first cohort: In 6 cities (Isfahan, Babol, Bandar Abbas, Sari, Kerman and Hamedan) 80% of people (14,400 people) receive the intervention (vaccine) after random allocation. Intervention is included intramuscular injection of vaccine candidates with conjugation of 25 \u03bcg RBD to tetanus toxin in a 2-dose program (days 0 and 28). This vaccine is made by the Finlay Institute of Vaccines.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]